



The ALPHA-MAN logo indicating the European consortium and the goal to get a therapy developed to cure the disabled patients.

Coordinator:

Paul Saftig, Ph.D., Director of Department.

Department of Biochemistry/ Christian-Albrechts-Universität Kiel.


Olshausenstr. 40 D-24098 Kiel, Germany.

Tel: ++49-4318802216 Fax: ++494318802238.


email : psaftig@biochem.uni-kiel.de

Participants:


No.	Participant Organization name	Country	Coordinator
1	Christian-Albrechts-University Kiel (CAU)	Germany	Judith Blanz/Paul Saftig
2	Zymenex (ZYMEX)	Denmark	Pia Ringholm/Jens Fogh
3	Copenhagen University Hospital (CUH)	Denmark	Allan Meldgaard Lund
4	Katholieke University Leuven (K.U.Leuven)	Belgium	Rudi D'Hooge
5	Manchester Children's University Hospital (CMMC)	United Kingdom	Simon Jones
6	Johannes- Gutenberg- University Mainz (UMG)	Germany	Michael Beck
7	Hospices Civils de Lyon (HCL)	France	Nathalie Guffon
8	University Tromsoe (UiT)	Norway	Øivind Nilssen
9	Danish Technological Institute (DTI)	Denmark	Trine Rolighed Thomsen / Nadia Taouatas
10	The Children's Memorial Health Institute Warsaw (IPCZD)	Poland	Anna Tylki-Szymańska
11	Larix (LARIX)	Denmark	Klaus Juel Olsen
12	Unilabs (UNILABS)	Denmark	Maria Lundberg



Structure and general flow of the projects within ALPHA-MAN



Successful therapy in alpha-mannosidosis mice. Disappearance of pathological storage observed using biochemical (left) and histological (right) methods.



Enzyme replacement therapy in clinical trials